Regulatory update for REZONIC (casopitant mesylate)

Regulatory update for REZONIC (casopitant mesylate)

GlaxoSmithKline (NYSE: GSK) confirmed today that it has received a complete response letterfrom the FDA related to the application for casopitant.

The company is reviewing this letter and will engage with the FDA to determine appropriate next steps.

A complete response letter is issued by FDA's Center for Drug Evaluation and Research (CDER) when the review of a file is completed and questions remain that preclude the approval of the application.

Casopitant was originally filed with the FDA on 29 May 2008, for the prevention of chemotherapy-induced nausea and vomiting (CINV) and post-operative nausea and vomiting (PONV).

GlaxoSmithKline--one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information please visit

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

Mutations in RIPK1 can cause uncontrolled cell death and inflammation, researchers discovered by studying families with an autoimmune disorder.